Claims for Patent: 11,370,755

Summary for Patent: 11,370,755

Title:	Compositions of trofinetide
Abstract:	This disclosure describes compounds of Formula (I), stereoisomers, side compounds thereof, pharmaceutical compositions and methods of manufacturing such compounds, using silylation reagents and producing compositions and products made using such methods. More particularly, this disclosure describes manufacture of trofinetide and side products, compositions and products containing such compounds, for pharmaceutical uses to treat neurodegenerative or neurodevelopmental disorders.
Inventor(s):	Clive Blower, Mathew Peterson, James Murray Shaw, James Anthony Bonnar, Etienne David Frank Philippe Moniotte, Martin Bernard Catherine Bousmanne, Cecilia Betti, Karel Willy Luc Decroos, Mimoun Ayoub
Assignee:	NEUREN PHARMACEUTICALS Ltd, Neuren Pharmaceuticals Ltd
Application Number:	US17/347,135
Patent Claims:	1. A composition comprising a compound of Formula (I): or a stereoisomer or pharmaceutically acceptable salt thereof and between about 0.001 wt % and about 2 wt % of a compound of Formula (II): 2. The composition according to claim 1, wherein the compound according to Formula (I) is a compound of Formula (Ia): or pharmaceutically acceptable salt thereof. 3. The composition according to claim 1, wherein the compound according to Formula (II) is a compound of Formula (IIa): or pharmaceutically acceptable salt thereof. 4. The composition according to claim 2, wherein said composition is obtained by: a) coupling (2S)-2-methylpyrrolidine-2-carboxylic acid and benzyloxycarbonyl-glycine in the presence of an activating reagent, silylating agent and a solvent, or b) coupling benzyloxycarbonyl-glycine and N-hydroxysuccinimide and then coupling the obtained benzyloxycarbonyl-glycine N-succinimidyl ester and (2S)-2-methylpyrrolidine-2-carboxylic acid in the absence or presence of an activating reagent, a solvent and in the absence or presence of a silylating agent; c) coupling the obtained ((S-1-(((benzyloxy)carbonyl)glycyl)-2-methylpyrrolidine-2-carboxylic acid) and (2S)-2-aminopentanedioic acid in the presence of an activating reagent, silylating agent and a solvent; d) obtaining ((S)-1-(((benzyloxycarbonyl)glycyl)-2-methylpyrrolidine-2-carbonyl)-L-glutamic acid and; e) deprotecting ((S)-1-(((benzyloxy)carbonyl)glycyl)-2-methylpyrrolidine-2-carbonyl)-L-glutamic acid to obtain the composition comprising the compound of Formula (Ia). 5. The composition according to claim 4, wherein the compound according to Formula (II) is a compound of Formula (IIa): or pharmaceutically acceptable salt thereof. 6. The composition according to claim 4, wherein deprotecting is achieved by hydrogenation. 7. The composition according to claim 6, wherein hydrogenation is performed in the presence of a Pd/C catalyst. 8. The composition according to claim 6, wherein hydrogenation is performed in the presence of a Pd/Si catalyst. 9. The composition according to claim 6, wherein the hydrogenation is performed using at least one solvent selected from the group consisting of water, ethyl acetate, isopropyl acetate, methanol, ethanol, and isopropanol, or mixtures thereof. 10. The composition according to claim 1, wherein the compound of Formula (II), or stereoisomer or pharmaceutically acceptable salt thereof, is present in an amount between about 0.001 wt % and about 0.2 wt %. 11. A composition comprising a compound of Formula (Ia): or pharmaceutically acceptable salt thereof, and between about 0.001 wt % and about 0.2 wt % of a compound of Formula (IIa): or pharmaceutically acceptable salt thereof. 12. The composition according to claim 1, wherein the compound of Formula (II), or stereoisomer or pharmaceutically acceptable salt thereof, is present in an amount between about 0.001 wt % and about 1 wt %. 13. The composition according to claim 1, wherein the compound of Formula (II), or stereoisomer or pharmaceutically acceptable salt thereof, is present in an amount between about 0.001 wt % and about 0.5 wt %. 14. The composition according to claim 1, wherein the compound of Formula (II), or stereoisomer or pharmaceutically acceptable salt thereof, is present in an amount between about 0.001 wt % and about 0.3 wt %. 15. The composition according to claim 1, wherein the compound of Formula (II), or stereoisomer or pharmaceutically acceptable salt thereof, is present in an amount between about 0.001 wt % and about 0.1 wt %. 16. The composition according to claim 5, wherein the compound of Formula (IIa), or stereoisomer or pharmaceutically acceptable salt thereof, is present in an amount between about 0.001 wt % and about 1 wt %. 17. The composition according to claim 5, wherein the compound of Formula (IIa), or stereoisomer or pharmaceutically acceptable salt thereof, is present in an amount between about 0.001 wt % and about 0.5 wt %. 18. The composition according to claim 5, wherein the compound of Formula (IIa), or stereoisomer or pharmaceutically acceptable salt thereof, is present in an amount between about 0.001 wt % and about 0.3 wt %. 19. The composition according to claim 5, wherein the compound of Formula (IIa), or stereoisomer or pharmaceutically acceptable salt thereof, is present in an amount between about 0.001 wt % and about 0.1 wt %. 20. The composition according to claim 2 comprising between about 98 wt % and about 100 wt % of the compound of Formula (Ia) on an anhydrous basis.